SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Norovirus Bivalent GI.1/GII.4 VLP Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: HIL-214

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Frazier Healthcare

            Deal Size: $14.2 million Upfront Cash: Undisclosed

            Deal Type: Collaboration July 30, 2021

            Details:

            HIL-214, a virus-like particle based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in which HIL-214 was well-tolerated and showed clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Appili Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 11, 2020

            Details:

            Appili Therapeutics to sponsor first clinical program in the world designed to assess the use of FUJIFILM Toyama Chemical’s favipiravir for COVID-19 as prophylaxis for outbreak control.